Procarbazine (Matulane) — Clinical FAQs

Question 1

What is Procarbazine FDA-approved to treat?

Accepted Answer

Procarbazine is FDA-approved for the following oncology indications: 1. Hodgkin lymphoma (Stage III and IV; component of MOPP and BEACOPP regimens).

Question 2

How does Procarbazine work (mechanism of action)?

Accepted Answer

Procarbazine is an oral methylhydrazine derivative prodrug that requires extensive metabolic activation to exert its antineoplastic effects. Autooxidation and hepatic microsomal metabolism generate reactive azo intermediates and the principal active metabolite, isopropylamine-azoprocarbazine, which liberates a methylating species that alkylates DNA at the N⁷ position of guanine, causing DNA strand breakage, inhibition of DNA/RNA/protein synthesis, and ultimately cell death. Procarbazine also weakly inhibits monoamine oxidase (MAO), contributing to clinically important drug and food interactions. Additionally, it generates hydrogen peroxide and free radicals as byproducts of its oxidative activation, adding oxidative DNA damage. It is cell-cycle nonspecific but preferentially active in the S phase.

Question 3

How is Procarbazine administered?

Accepted Answer

Procarbazine is administered Oral (PO). Available as 50-mg capsules for oral administration.

Question 4

What are the most common side effects of Procarbazine?

Accepted Answer

The most commonly reported side effects of Procarbazine (≥10% incidence) include: Nausea and vomiting (common; often dose-limiting; moderately emetogenic — use 5-HT3 antagonist ± dexamethasone prophylaxis), Anorexia and weight loss, Myelosuppression: leukopenia, thrombocytopenia, anemia (nadir approximately 4 weeks), Fatigue and malaise, CNS toxicity: dizziness, drowsiness, somnolence, paresthesias, headache, insomnia, mood changes, confusion and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Procarbazine have a black box warning?

Accepted Answer

Yes. Procarbazine carries FDA black box warning(s) regarding: 1. Myelosuppression: Procarbazine causes significant dose-dependent bone marrow depression — leukopenia, thrombocytopenia, and anemia — which may be severe and life-threatening. Monitor blood counts carefully throughout therapy. 2. Carcinogenesis: Procarbazine is a potent carcinogen and mutagen. Secondary acute myelogenous leukemia (AML) and other secondary malignancies have been reported following procarbazine-containing regimens (particularly MOPP). The risk is substantially higher with MOPP than with ABVD for Hodgkin lymphoma; ABVD is now preferred for most patients. Procarbazine has been designated as a known human carcinogen.

Question 6

Is Procarbazine safe during pregnancy?

Accepted Answer

Procarbazine pregnancy safety: Category D — Procarbazine is teratogenic in animals and causes fetal harm. It should not be administered during pregnancy. Women of childbearing potential must use highly effective contraception during therapy and for at least 6 months after the final dose. Males should use contraception during and for at least 3 months after therapy. Sperm cryopreservation should be offered prior to initiating treatment given the high risk of permanent azoospermia.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Procarbazine — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms